An interventional study of Digimer DS8R in Cerebral Palsy Spastic Hemiplegic, sponsored by University of Leeds. Recruiting at 1 site in United Kingdom. Open to participants aged 12 Years to 21 Years. Per ClinicalTrials.gov, last updated 2026-05-06.
Sponsored by University of Leeds · Not applicable, Interventional, and Treatment
This work will examine if a technique called Transcutaneous Spinal cord stimulation (tSCS), when used with concurrent specific arm and hand exercises, helps improve arm and hand movements in CYP with HCP.
Does Transcutaneous Spinal Cord Stimulation (tSCS), when combined with specific arm and hand exercises, improve upper limb function in children and young people (CYP) with Hemiplegic Cerebral Palsy (HCP)?
-To determine the feasibility and effectiveness of Transcutaneous Spinal Cord Stimulation (tSCS) combined with targeted arm and hand exercises in improving the upper limb function in children and young people with Hemiplegic Cerebral Palsy (HCP).
Cerebral palsy (CP) is a condition that affects movement and posture due to brain development issues in babies or young children. Hemiplegic CP (HCP) is a condition where one side of the body is paralysed. Symptoms like stiffness in the arms and legs usually appear early and can make everyday tasks, such as reaching or holding objects difficult. Improving arm and hand function is crucial for increasing independence and quality of life for children with HCP. This study investigates a technique called Transcutaneous Spinal Cord Stimulation (tSCS). tSCS uses sticky pads placed on the skin to deliver a mild electrical current. This current stimulates nerves to help them send signals to the muscles, potentially improving arm and hand movements. Research has demonstrated that tSCS can provide benefits in the lower limb for children and young people (CYP) with CP, those with spinal cord injuries and healthy individuals. In this project, we will test the feasibility and effectiveness of tSCS in 18 CYP (aged 12-21 years) with HCP. The participant will attend two sessions. Each session will last approximately 60-90 minutes and will include:
1,936 studies on the registry are indexed under Cerebral Palsy; 458 are open to participants now.
This study's planned enrollment of 18 is below the median of 34 across 1,431 interventional studies indexed under Cerebral Palsy.
Browse Cerebral Palsy studies →University of Leeds is the lead sponsor of 206 studies on the registry; 25 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One session will involve transcutaneous spinal cord stimulation (tSCS) combined with ULTT
Device: Digimer DS8R
one session with ULTT only (no stimulation; tSCS)
Transtcuatne Electrical stimulation will be delivered using the Digimer DS8R. The tSCS will be administered in one session only, during which participants will receive continuous tSCS simultaneously with Upper Limb Motor Training (ULTT).
Participants with stimulation-site skin reaction (Yes/No; photographic assessment)
Standardised photographs of the back will be obtained at each time point and reviewed by an independent clinician (not part of the study team). A skin reaction is defined as any visible erythema at/near the electrode site and will be recorded on a Yes/No erythema scale (0 = No erythema; 1 = Yes erythema). Results will be reported as the number and proportion of participants with ≥1 skin reaction during the session and by time point.
Time frame: At the first session: Baseline (pre-tSCS) and immediately post-tSCS
Heart Rate Category (beats per minute)
Heart rate will be measured immediately before and after tSCS using an OMRON M3 device. For each participant, a blinded independent clinician will classify the post-stimulation change relative to Baseline as one of three categories: Increased, Decreased, or No Apparent Change. Study results will be summarised as the number and proportion of participants in each category and described narratively.
Time frame: [Time Frame: Baseline (pre-tSCS); During tSCS (10 minutes after start); Immediately post-tSCS (within 10 minutes after end) during a single session.
Hand Strength Index (dynamometry)
Handgrip and pinch strength will be measured with handheld dynamometers (adjustable handle/pads; peak-hold). At each time point, participants perform 3 maximal attempts per measure; the average (mean) is calculated for handgrip and for pinch. Results will be summarised as mean (SD) by timepoint and change from pre to post within each session (Post - Pre). Component means (handgrip and pinch) will be presented descriptively as supportive information.
Time frame: Session 1[first visit]: Pre (Baseline, before tSCS); Session 1 [first visit]: Post (immediately after tSCS, within 10 minutes); Session 2 [second visit]: Pre (Baseline, before tSCS); Session 2 [sv]: Post (immediately after tSCS, within 10 minutes)
Jebsen-Taylor Hand Function Test total time (seconds)
Hand function will be assessed with the Jebsen-Taylor Hand Function Test (JTHFT). The protocol includes three subtests: (1) picking up small common objects; (2) stacking checkers; (3) lifting large light and large heavy cans (\~1 lb). Each subtest is timed to completion. Testing is administered with the less affected hand first, then the more affected hand; the primary outcome is the Total Score for the more affected hand. Results will be summarised as mean (SD) seconds by timepoint and change from pre to post within each session (Post - Pre). (Scores for the less affected hand may be presented descriptively as supportive data.)
Time frame: Session 1[first visit]: Pre (Baseline, before tSCS); Session 1 [first visit]: Post (immediately after tSCS, within 10 minutes); Session 2 [second visit]: Pre (Baseline, before tSCS); Session 2 [sv]: Post (immediately after tSCS, within 10 minutes)
Muscle Activity: Mean motor threshold to elicit ≥50 µV sEMG response (mA) - Delsys Trigno / Digitimer DS8R
Muscle activity will be assessed with surface EMG (Delsys Trigno). Sensors will be placed on the more affected arm over the abductor pollicis brevis, flexor carpi radialis, and extensor carpi radialis longus. Single spinal pulses (1 ms biphasic square-wave) will be delivered every \~5 s using a Digitimer DS8R. For each muscle at each time point, the motor threshold is defined as the lowest stimulation amplitude (mA) that produces an evoked sEMG response ≥50 µV. The participant-level outcome is the mean motor threshold (mA) across the three muscles. Results will be summarised as mean (SD) mA by timepoint and change from Baseline to Post.
Time frame: Session 1: Pre (Baseline, before tSCS); Session 1: Post (immediately after tSCS, within 10 minutes); Session 2: Pre (Baseline, before tSCS); Session 2: Post (immediately after tSCS, within 10 minutes).
Modified Ashworth Scale (0-4; higher = worse) - worst upper-limb muscle score (more affected limb)
Spasticity will be assessed with the Modified Ashworth Scale (MAS), scored 0, 1, 1+, 2, 3, 4 (0 = no increase in tone; 4 = rigid; higher scores indicate worse spasticity). The following muscles on the more affected upper limb will be tested in a fixed order: elbow flexors, wrist flexors, finger flexors. At each timepoint, the primary outcome is the worst (highest) MAS score across the tested muscles. Results will be summarised as median by timepoint and change from Pre to Post within each session (Post - Pre).
Time frame: Session 1[first visit]: Pre (Baseline, before tSCS); Session 1 [first visit]: Post (immediately after tSCS, within 10 minutes); Session 2 [second visit]: Pre (Baseline, before tSCS); Session 2 [sv]: Post (immediately after tSCS, within 10 minutes)
Systolic Blood Pressure Category (mmHg)
Systolic blood pressure will be measured immediately before and after tSCS using an OMRON M3 device. For each participant, a blinded independent clinician will classify the post-stimulation change relative to Baseline as one of three categories: Increased, Decreased, or No Apparent Change. Study results will be summarised as the number and proportion of participants in each category and described narratively.
Time frame: Baseline (pre-tSCS); During tSCS (10 minutes after start); Immediately post-tSCS (within 10 minutes after end) during a single session.
Diastolic Blood Pressure Category (mmHg)
Diastolic blood pressure will be measured immediately before and after tSCS using an OMRON M3 device. For each participant, a blinded independent clinician will classify the post-stimulation change relative to Baseline as one of three categories: Increased, Decreased, or No Apparent Change. Study results will be summarised as the number and proportion of participants in each category and described narratively.
Time frame: Baseline (pre-tSCS); During tSCS (10 minutes after start); Immediately post-tSCS (within 10 minutes after end) during a single session.
Participant-reported experience with stimulation - response frequencies (project-specific questionnaire)
A project-specific Participant Feedback Questionnaire (PFQ-tSCS), completed by the participant or caregiver, will capture experience with stimulation across predefined domains: comfort, ease of participation, sensations during the session, skin reactions, discomfort/adverse effects, and overall satisfaction. Items use ordered categorical response options (e.g., None/Mild/Moderate/Severe or Strongly disagree → Strongly agree), plus optional free-text. Outcome data will be reported as the number and proportion of participants in each response category for each item; free-text responses will be summarised narratively.
Time frame: Immediately post-final tSCS session [first session] (within 10 minutes), single administration.
ABILHAND-Kids total raw score (0-42; higher = better manual ability)
Manual ability will be assessed with the ABILHAND-Kids Questionnaire (21 items; response options: Impossible = 0, Difficult = 1, Easy = 2). The total raw score is the sum across items (higher scores indicate better manual ability). The questionnaire may be completed by the participant or a caregiver proxy per instrument guidance. Results will be summarised as mean (SD) total score by timepoint and change from Pre to Post within each session (Post - Pre)
Time frame: Session 1[first visit]: Pre (Baseline, before tSCS); Session 1 [first visit]: Post (immediately after tSCS, within 10 minutes); Session 2 [second visit]: Pre (Baseline, before tSCS); Session 2 [sv]: Post (immediately after tSCS, within 10 minutes).
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.